Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
University of Colorado, Colorado Health Sciences Center details research in cancer vaccines
March 2nd, 2007
A report, "TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors," is newly published data in Journal of Neuro-Oncology. "TGF-beta2 secretion by high grade gliomas has been implicated as one of the major factors contributing to tumor growth, alterations in the host immune response to tumor, and failure of gliomas to respond to current immunotherapy strategies. We hypothesized that targeted delivery and inhibition of TGF-beta2 by TGF-beta2 antisense oligonucleotides (AS-ODNs) would overcome tumor-induced immunosuppression and enhance the capacity of tumor vaccines to eradicate established brain tumors," researchers...
Source: Drug Week (2007-03-02)
|
